Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Other financing activities (2021 - 2025)

Lexaria Bioscience's Other financing activities history spans 3 years, with the latest figure at $167219.0 for Q1 2025.

  • Quarterly results put Other financing activities at $167219.0 for Q1 2025, changed N/A from a year ago — trailing twelve months through Feb 2025 was $1.2 million (changed N/A YoY), and the annual figure for FY2021 was $85000.0, changed.
  • Other financing activities for Q1 2025 was $167219.0 at Lexaria Bioscience, up from -$300000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $1.2 million in Q1 2022 to a low of -$300000.0 in Q2 2022.
  • The 3-year median for Other financing activities is $126109.5 (2021), against an average of $288054.8.